Valuation: Clarity Pharmaceuticals Ltd

Capitalization 1.33B 935M 806M 727M 698M 1.27B 85.88B 8.6B 3.44B 41.19B 3.51B 3.43B 147B P/E ratio 2026 *
-11.7x
P/E ratio 2027 * -12.3x
Enterprise value 1.17B 822M 708M 639M 614M 1.12B 75.5B 7.56B 3.03B 36.21B 3.08B 3.02B 129B EV / Sales 2026 *
-
EV / Sales 2027 * 133x
Free-Float
73.99%
Yield 2026 *
-
Yield 2027 * -
1 day+3.17%
1 week-0.83%
Current month-0.83%
1 month+31.14%
3 months+17.76%
6 months+12.93%
Current year+5.92%
1 week 3.07
Extreme 3.07
3.61
1 month 2.81
Extreme 2.81
4
Current year 2.69
Extreme 2.69
4
1 year 1.43
Extreme 1.43
5.87
3 years 0.68
Extreme 0.675
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 2024-10-10
Chief Executive Officer - 2009-12-31
Director of Finance/CFO - 2022-04-03
Director TitleAgeSince
Chairman - 2013-10-31
Director/Board Member - 2010-09-30
Director/Board Member 72 2016-03-28
Change 5d. change 1-year change 3-years change Capi.($)
+3.17%-0.83%+26.50%+297.78% 935M
-0.61%-5.35%+12.03%+92.93% 44.16B
+0.92%-4.81%+49.26%+14.90% 40.5B
-2.40%-6.16%+87.11%+608.08% 30.21B
-0.44%-7.92%-6.69%-21.33% 25.47B
+2.54%-9.65%+53.01%-34.70% 19.22B
-2.62%-6.49%+4.16%-31.60% 16.5B
+5.20%+0.37%+47.19%+154.57% 12.64B
+1.14%-8.92%-15.02%+994.93% 11.72B
+4.43%-0.31%+55.98% - 11.51B
Average +1.13%-4.65%+31.35%+230.62% 21.29B
Weighted average by Cap. +0.31%-5.14%+33.66%+174.98%

Financials

2026 *2027 *
Net sales - 9.67M 6.78M 5.85M 5.28M 5.07M 9.24M 623M 62.41M 25M 299M 25.46M 24.91M 1.07B
Net income -111M -77.56M -66.87M -60.36M -57.92M -106M -7.13B -714M -286M -3.42B -291M -285M -12.22B -104M -72.7M -62.68M -56.58M -54.29M -99M -6.68B -669M -268M -3.2B -273M -267M -11.46B
Net Debt -161M -113M -97.38M -87.91M -84.35M -154M -10.38B -1.04B -416M -4.98B -424M -415M -17.8B -47.44M -33.29M -28.7M -25.91M -24.86M -45.33M -3.06B -306M -123M -1.47B -125M -122M -5.25B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Employees
88
Date Price Change Volume
26-03-06 3.580 $ +3.17% 1,160,789
26-03-05 3.470 $ +11.58% 1,640,368
26-03-04 3.110 $ -8.80% 1,657,499
26-03-03 3.410 $ +0.59% 944,981
26-03-02 3.390 $ -6.09% 2,023,969
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.580AUD
Average target price
7.250AUD
Spread / Average Target
+102.51%

Annual profits - Rate of surprise